Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discounts will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
Beam Therapeutics has raked in $135 million in its second formal financing round. Since launching in May 2018, the biotech firm has raised over $220 million to develop therapies that use base-editing technology from David R. Liu’s lab at Broad Institute of MIT and Harvard. These next-generation gene-editing tools allow researchers to make single-nucleotide base changes in DNA, an approach that could offer a fix for the swath of genetic diseases driven by an error in a single letter. Beam says it will use the funds to expand its team and move programs toward the clinic.
This article has been sent to the following recipient: